核医学

Japanese
Title	甲状腺腫瘍患者の血中サイログロブリン濃度測定の有用性
Subtitle	原著
Authors	池窪勝治, 濱崎利子, 山田明子, 尾藤早苗, 杤尾人司, 才木康彦, 伊藤秀臣, 森本義人, 赤水尚史, 沢田賢三, 石原隆, 森徹, 石川稔晃*, 高坂唯子, 御前隆, 飯田泰啓, 遠藤啓吾, 小西淳二, 鳥塚莞爾**
Authors(kana)
Organization	神戸市立中央市民病院核医学科, 内科, 外科, **京都大学医学部核医学科
Journal	核医学
Volume	20
Number	3
Page	313-319
Year/Month	1983/4
Article	原著
Publisher	日本核医学会
Abstract	「要旨」未治療および治療後の甲状腺分化癌74例と腺腫53例の血中Tg濃度を2抗体RIAキット (栄研) により測定し, 臨床的意義を検討した. また, 一部の症例について腫瘍重量と血中Tg値の関係および甲状腺剤投与の血中Tg値への影響を観察した. 正常者 (31) で血中Tgは93%に検出され, 0～30ng/mlに分布し, 平均11.4±7.6 (S.D.) ng/mlであった. 未治療分化癌 (22) および腺腫 (47) の血中Tg値は85～86%で高値であった. 術後, 再発や転移のある分化癌 (13) の全例が高値を示し, 転移の証明されないもののTg値は全摘 (17) 症例で6.7±15.4ng/ml, 亜全摘 (14) 症例で34.0±27.0ng/mlであった. 分化癌 (5) と腺腫 (2) の治療後の観察では再発例で高値を示した. 腫瘍の大きさとTg値の関係は, 統計上有意な相関は認めなかった. Tg値は甲状腺剤投与で抑制され, 術後の補償療法の中止で上昇し, TSHにより制御されていることが示唆された. 以上Tg値の測定は甲状腺腫瘍の診断と治療後の観察に有用であり, ルチンに行うべきであると考えられた.
Practice	臨床医学：一般
Keywords	Serum thyroglobulin, double-antibody RIA, differentiated thyroid cancer, thyroid adenoma
English
Title	Clinical Usefulness of The Measurement of Serum Thyroglobulin in Patients with Thyroid Tumors
Subtitle	Original Articles
Authors	Katsuji IKEKUBO, Toshiko HAMASAKI, Akiko YAMADA, Sanae BITO, Hitoshi TOCHIO, Yasuhiko SAIKI, Hidetomi ITO, Yoshito MORIMOTO, Takashi AKAMIZU, Kenzo SAWADA, Takashi ISHIHARA, Toru MORI, Toshiaki ISHIKAWA*, Tadako KOUSAKA, Takashi MISAKI, Yasuhiro IIDA, Keigo ENDO, Junji KONISHI, Kanji TORIZUKA**
Authors(kana)
Organization	Department of Nuclear Medicine, Department of Internal Medicine, Department of Surgery, Kobe Central Municipal Hospital, **Department of Nuclear Medicine, Kyoto University
Journal	The Japanese Journal of nuclear medicine
Volume	20
Number	3
Page	313-319
Year/Month	1983/4
Article	Original article
Publisher	THE JAPANESE SOCIETY OF NUCLEAR MEDICINE
Abstract	[Summary] Measurements of serum thyroglobulin (Tg) were performed in 74 patients with differentiated thyroid cancer and in 53 patients with thyroid adenoma. Serum Tg was determined using double antibody Tg RIA kit (Eiken Co., Tokyo) The correlation of serum Tg with tumor weight removed at operation was examined in 12 patients with differentiated cancer and 14 patients with adenoma. The effects of thyroid suppressive or replacement therapy on Tg levels in 7 tumor patients were also studied. Serum Tg was detectable in 93% of 31 normal subjects, with a mean value of 11.4+-7.6 (SD) ng/ml (range, 0 to 30ng/ml). Serum Tg levels were elevated in 85-86% in untreated 22 differentiated cancer and 47 adenoma. High Tg levels were found in all 13 thyroidectomized cancer patients with evidence of recurrence or metastases. Of 31 thyroidectomized cancer patients without evidence of residual tumor, mean serum Tg level for the total thyroidectomy group (n = 17, 6.7+-15.4ng/ml) was significantly different from the mean of subtotal thyroidectomy group (n = 14, 34.0+-27.0ng/ml) (p < 0.05). Tg levels were followed after treatment of surgery or radioiodine abration in 5 patients with differentiated cancer and 2 patients with adenoma. A patient with residual cancer had increased Tg levels. There was no statistically correlation between serum Tg concentrations and tumor weight. A marked reduction of serum Tg was observed in tumor patients during thyroxine suppression therapy. In 2 patients with residual cancer, serum Tg and TSH levels increased after T3 withdrawal. These results suggest that Tg release is controlled by TSH. We concluded that serum Tg determination is very useful and should be used as a routine test in the evaluation and management of patients with differentiated thyroid cancer.
Practice	Clinical medicine
Keywords	Serum thyroglobulin, double-antibody RIA, differentiated thyroid cancer, thyroid adenoma

【全文PDF】